Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...

After six weeks in the hospital, 23‑year‑old Daniel Cressy leaves with hope for a functional cure and a future where he can ...

Novo Nordisk will be happy with the results after Pfizer has dropped two SCD assets in recent years. Credit: JHVEPhoto / ...

Novo Nordisk says it plans to apply for regulatory approval of its sickle cell disease, etavopivat, in the second half of ...

Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...

Topline data for the once-daily PKR activator etavopivat demonstrate a 27% reduction in vaso-occlusive crises and a robust hematologic response in patients with SCD.

Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating ...

Negative descriptors were present in 15% of notes for sickle cell patients; 14% of notes for patients with opioid use ...

Sickle cell disease (SCD) is an inherited disorder that affects over 100,000 people in the United States, according to the Sickle Cell Disease Association of America, of that number, the Centers for ...

Novo Nordisk acquired rights to etavopivat when it bought Forma Therapeutics for $1.1 billion in 2022, when the drug was in ...

Scientists from Johns Hopkins Medicine and eight other institutions in the United States, Africa and Europe say they have identified a potential new gene target that could be edited to treat sickle ...

Study finds sickle cell disease bias in clinical notes is linked more to opioid use than race or chronic pain in healthcare ...